Can You Advertise Wegovy Online in 2026?

Wegovy is Novo Nordisk's branded semaglutide for chronic weight management. Unlike Ozempic (which is technically labeled for diabetes), Wegovy carries the FDA-approved indication for weight loss in qualifying patients. Telehealth brands can absolutely market services that include Wegovy as a prescribing option, but the same brand-versus-class distinction applies, plus a specific cash-pay vs insurance dimension that often decides what your campaign looks like in practice.

Here is the plain-English answer.

What You Can Advertise

A telehealth service that includes prescribing semaglutide for weight loss in qualifying patients. The service is your product; semaglutide (including Wegovy when clinically appropriate) is part of the clinical workflow.

Process transparency around how the consultation works, what qualification looks like, and how insurance navigation is handled if you offer it.

Provider credentialing, pharmacy partnerships, and the clinical experience your brand provides.

Mechanism-of-action education about GLP-1 receptor agonists.

What You Cannot Advertise

Wegovy as your branded product, the way Novo Nordisk can. Telehealth brands do not own the Wegovy brand and cannot promote it in the way an FDA-approved manufacturer can.

Specific weight loss outcome guarantees. The same outcome-claim rules that apply across telehealth weight loss apply to brand-name medications.

Compounded versions presented as equivalent to Wegovy. Equivalence claims trigger FDA concern and platform policy violations.

Personal-attribute targeting. "Struggling with weight?" gets flagged by Meta's healthcare policy.

The Cash-Pay vs Insurance Distinction

Wegovy retail pricing makes a cash-pay subscription model expensive at $1,200-1,800 monthly. Most telehealth brands that offer Wegovy run an insurance-coordinated model: the brand helps the patient navigate prior authorization, copay support, and pharmacy selection. The marketing for this model looks different from compounded semaglutide marketing.

Insurance-coordinated marketing centers on access, navigation, and the clinical relationship. "We help you get covered." "Our team handles prior authorization."

Cash-pay compounded semaglutide marketing centers on simplicity, transparency, and the medication class. "Compounded semaglutide, $299/month, no insurance required."

Brands trying to run both models through one creative engine consistently struggle. The audiences and decision criteria are different. For more, see cash pay vs insurance GLP-1 brands.

Platform Notes

Meta will flag ads that lead with Wegovy as a brand promotion. Reframing around semaglutide therapy or GLP-1 weight loss services is the standard fix.

Google Search allows bidding on "Wegovy" keywords with LegitScript certification and clean landing pages. The non-branded search demand is significant for telehealth brands offering insurance navigation services.

TikTok restricts brand-name medication mentions in healthcare advertising more strictly than Meta. Wegovy-specific TikTok creative is generally not viable.

How Insurance-Coordinated Telehealth Markets Wegovy

The strongest creative for insurance-coordinated GLP-1 weight loss telehealth centers on the navigation pain. Patients are tired of insurance company runarounds, prior authorization denials, and pharmacy hassles. The brands that win frame the offering as "we handle the hard part of getting GLP-1 covered."

Process transparency content is the highest-performing creative format. A provider or care coordinator walking through what insurance navigation actually looks like, what timeline to expect, and what happens if the prior authorization is denied. Calm, specific, useful.

How Cash-Pay Compounded Brands Position Around Wegovy

Most cash-pay compounded semaglutide brands do not center their marketing on Wegovy at all. They lead with the medication class, the compounded formulation, and the price simplicity. Wegovy is referenced when the audience expects it, but not promoted.

Avoid framing compounded semaglutide as a direct equivalent to Wegovy. FDA scrutiny on equivalence claims has tightened, and the framing creates regulatory exposure that is not worth the marketing benefit.

The Short Version

You can advertise telehealth services that include Wegovy in 2026. You generally cannot promote Wegovy as your branded product. The bigger decision is the business model: insurance-coordinated programs market around navigation and access; cash-pay compounded programs market around the medication class and price simplicity. Pick a model, build the right creative for it, and stay inside the brand-versus-class line.